Related Experiment Video
Updated: Sep 6, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival
Federico Cucchiara1, Iacopo Petrini2, Antonio Passaro3
1Department of Clinical and Experimental Medicine, Unit of Clinical Pharmacology and Pharmacogenetics, University of Pisa, Pisa, Italy.
Background:
Small cell lung cancer (SCLC) is an aggressive tumor, and despite its sensitivity to chemotherapy and radiotherapy, patients usually have a short survival. There are no clinically relevant predictive factors of responses to therapies, and therapeutic options are still limited.
Materials And Methods:
Clinical data and somatic mutations of genes included in the MSK-IMPACT panel were retrieved from cBioPortal for 108 SCLCs and analyzed to identify mutated gene networks. Results were validated in an independent cohort of 54 SCLCs, whose information was also available from cBioPortal.
Results:
Different networks were observed in tumors of short and long survivors. Degree (K) and betweenness (B) are key features that characterize a gene in its network of related mutations. By comparing their B/K ratio, 2 signatures of mutated genes were identified, describing short (IL-7R, NTRK2, HNF-1A) and long survivors (NBN, PTPN-11, IRS-1, INPP-4A, PIK-3CG, HGF, LATS-2, SMARCA-4, FLT-3, EIF-4A2, SPEN, PAX-5, SH2-D1A, ARID-1A, HOXB-13, ERCC-4, FANCA, FH, FGFR-2, MST-1R, SMAD-4, DDR-2, IGF-1R, PIK-3CB). Patients with at least 1 mutated gene of the short signature had a worse median overall survival of 8 versus 28 months (P < .001). Patients with at least 1 mutated gene of the long signature had a better median overall survival of 39 versus 20 months (P = .004). The value of the short signature was further confirmed in an independent cohort of SCLCs.
Conclusion:
The networks of mutated genes could help subclassify SCLCs based on their somatic mutations and aid in identifying a subset of tumors with poor prognosis.
Insights
Identifying mutated gene networks in small cell lung cancer (SCLC) can predict patient survival. Specific gene signatures correlate with significantly shorter or longer overall survival, aiding in prognosis.
Area of Science:
- Oncology
- Genetics
- Bioinformatics
Background:
- Small cell lung cancer (SCLC) is aggressive with limited therapeutic options and poor survival.
- Current predictive factors for SCLC treatment response are lacking.
- Therapeutic strategies for SCLC remain limited.
Purpose of the Study:
- To identify mutated gene networks in SCLC.
- To correlate these networks with patient survival outcomes.
- To discover potential predictive biomarkers for SCLC prognosis.
Main Methods:
- Clinical data and somatic mutations from 108 SCLCs were analyzed using MSK-IMPACT panel data from cBioPortal.
- Mutated gene networks were identified and characterized by their degree (K) and betweenness (B) centrality.
- Results were validated in an independent cohort of 54 SCLCs.
Main Results:
- Two distinct mutated gene network signatures were identified, differentiating short and long survivors.
- The 'short signature' (IL-7R, NTRK2, HNF-1A) was associated with significantly worse median overall survival (8 vs. 28 months).
- The 'long signature' (e.g., NBN, PTPN-11, SMARCA-4) was linked to better median overall survival (39 vs. 20 months).
Conclusions:
- Mutated gene networks can be used to subclassify SCLC.
- These networks may help identify SCLC subsets with poor prognosis.
- This approach could lead to improved patient stratification and targeted therapies.
Related Concept Videos
02:26Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
01:21Cancer Survival Analysis